Cellceutix Corp (CTIX) 2.7200 $CTIX Cellceutix Reports

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cellceutix Corp (CTIX) 2.7200 $CTIX

Cellceutix Reports Results for Quarter Ended March 31, 2015; Enrollment for Oral Mucositis Studies to Begin This Month
Marketwired - Wed May 13, 6:01AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, today announced its financial results for the three months ended March 31, 2015. A detailed report of the third quarter fiscal 2015 has been filed in a Form 10-Q with the Securities and Exchange Commission.

Cellceutix Selects Independent Directors and Committee Members
Marketwired - Mon Apr 27, 6:00AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce the selection of Dr. Barry Alan Schechter, Dr. Zorik Spektor and Mark Tobin as qualified independent directors and committee members of the Company's Board of Directors.

CellCeutix: Comparing Brilacidin With SoC Daptomycin
Kanak Kanti De - at Seeking Alpha - Tue Apr 21, 12:37PM CDT


Cellceutix Provides Corporate Update
Marketwired - Tue Apr 21, 9:06AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to provide shareholders with a comprehensive update on current corporate activity and pipeline development.

Cellceutix PIND Meeting Scheduled With FDA for Hidradenitis Suppurativa
Marketwired - Mon Apr 13, 6:00AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted the Company's request for a Pre-Investigational New Drug (PIND) meeting to discuss the Company's plans for a Phase 2 clinical trial with one of the Company's Host Defense Proteins (HDPs) for the treatment of hidradenitis suppurativa. The meeting is scheduled during the third week of May.

Cellceutix Corporation - Product Pipeline Review - 2015
M2 - Thu Apr 09, 1:48AM CDT
Summary

Cellceutix closes $30M stock purchase agreement
Seeking Alpha - at Seeking Alpha - Wed Apr 01, 7:59AM CDT


Cellceutix Enters Into a $30 Million Common Stock Purchase Agreement
Marketwired - Wed Apr 01, 6:00AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to inform shareholders that Cellceutix has signed a $30 million stock purchase agreement with Aspire Capital Fund, LLC. Pursuant to the Agreement, Aspire has committed to purchase over the next 3 years up to $30 million of Cellceutix's common stock based on the prevailing market prices at the time of each sale. The timing of the purchases will be at the sole discretion of Cellceutix. Aspire Capital has previously provided the Company with $30 million in equity capital in two similar transactions. Additional details of the Agreement with Aspire Capital have been filed in a Report on Form 8-K with the U.S. Securities and Exchange Commission.

Tenth Cohort Completed in Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin, No Adverse Events Reported
Marketwired - Tue Mar 24, 7:29AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that the tenth cohort in the Company's Phase 1 clinical trial of Kevetrin for advanced solid tumors being conducted at Harvard's Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center has been completed. Patients in the tenth cohort were treated with 450 mg/m2 of Kevetrin with no adverse events reported.

Cellceutix Advancing Treatment for Hidradenitis Suppurativa, Pre-IND Meeting Request to Food and Drug Administration
Marketwired - Mon Mar 16, 7:33AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to inform shareholders that further to the Company's press release on March 2, 2015, Cellceutix is this week submitting a request with the U.S. Food and Drug Administration for a pre-Investigational New Drug (IND) meeting to initiate a clinical study for one of the Company's Host Defense Proteins (HDPs) for the treatment of hidradenitis suppurativa (HS).

Ulcerative Colitis Therapeutics Pipeline Review 2015 - 66 Companies & 99 Drug Profiles
M2 - Tue Mar 03, 6:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/kwqzpf/ulcerative) has announced the addition of the "Ulcerative Colitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ulcerative Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ulcerative Colitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ajinomoto Pharmaceuticals Co., Ltd. - AlphaMab Co., Ltd - Altheus Therapeutics, Inc. - Am-Pharma B.V. - Amgen Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Athersys, Inc. - Atlantic Healthcare plc - Avaxia Biologics, Inc. - Biocon Limited - BioLineRx, Ltd. - Bristol-Myers Squibb Company - Celgene Corporation - Cellceutix Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Cosmo Pharmaceuticals S.p.A - Dr. Falk Pharma GmbH - Drais Pharmaceuticals, Inc. - Effimune SAS - Emergent BioSolutions Inc. - Enceladus Pharmaceuticals BV - Epirus Biopharmaceuticals, Inc. - Euroscreen S.A. - Farmacija d.o.o. Tuzla - Flexion Therapeutics, Inc. - Galapagos NV - Genentech, Inc. For more information visit http://www.researchandmarkets.com/research/kwqzpf/ulcerative
FLXN: 18.45 (-0.20), EBS: 30.72 (+0.47), AMGN: 162.36 (+0.38), BMY: 67.64 (+0.19), AZN: 69.29 (-0.81), CCXI: 7.21 (-0.09), ATHX: 1.27 (-0.01), CELGZ: 2.60 (-0.10)

Cellceutix to Expand Its Skin Product Pipeline
Marketwired - Mon Mar 02, 8:32AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that it is expanding its dermatology pipeline to include novel Human Defense Protein (HDP) mimetics for the treatment of chronic skin conditions, such as acne vulgaris, rosacea, and hidradenitis suppurativa (HS). Recently conducted pre-clinical research supports these conditions as targets due to the robust antimicrobial and anti-inflammatory properties of Cellceutix's HDP mimetics. These are conditions for which there is no consistently effective treatment, as in the case of HS, or there is room to improve upon current therapies, as in acne vulgaris or rosacea. In these conditions, topical antibiotics have been used, with mixed or disappointing results, most likely due to a lack of anti-inflammatory activity in concert with an inability to treat bacteria, such as Propionibacterium acnes, that are growing increasingly resistant to current therapies. The HDP mimetics can overcome both hurdles: they have anti-inflammatory properties and they can kill key bacteria without promoting further resistance. The latter is important, because traditional antibiotics, when chronically used, are likely to promote resistance, whereas HDP mimetics, given their unique structure and mechanism of action, are unlikely to promote resistance.

Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 224.63 (+1.81), ACT: 296.60 (-0.86), MDT: 76.42 (+0.16), XON: 40.08 (-0.90), CTIC: 1.80 (+0.04), PFNX: 13.70 (+0.60), JNJ: 102.30 (+0.47), ANTM: 161.37 (+1.37), NVAX: 8.54 (-0.09), SHPG: 254.45 (+3.99), ABBV: 65.99 (+0.02), TBPH: 14.69 (-0.24), SNY: 50.52 (-0.27), ALQA: 4.48 (-0.27), REGN: 489.01 (-2.42), ONCY: 0.71 (unch), PFE: 33.99 (+0.05), SLXP: 172.96 (+0.15), EPRS: 5.61 (-0.14), AMGN: 162.36 (+0.38), NKTR: 11.13 (+0.20), ZTS: 46.49 (+0.21), GILD: 109.30 (+0.56), ACHN: 9.57 (+0.05), GERN: 3.89 (-0.02)

IHUB Most Posted And Most Read Stocks Do Not Perform Well
Anthony Cataldo - at Seeking Alpha - Wed Feb 11, 8:43AM CST

PPHM: 1.37 (+0.05)

An Interview With Cellceutix CEO Leo Ehrlich
KarinCA - at Seeking Alpha - Mon Feb 09, 9:31AM CST

MRK: 60.23 (+0.45)

Cellceutix: Why An Uplisting Is Not Possible Right Now
Bleecker Street Research - at Seeking Alpha - Fri Feb 06, 1:26PM CST


$CTIX - Cellceutix Undervalued By 90+%; Expect A Short Squeeze Soon
KarinCA - at Seeking Alpha - Thu Jan 29, 3:13PM CST

JNJ: 102.30 (+0.47), CBSTZ: 0.06 (unch), ACT: 296.60 (-0.86), PFE: 33.99 (+0.05), MRK: 60.23 (+0.45), AMGN: 162.36 (+0.38), LLY: 72.90 (-0.16), ABBV: 65.99 (+0.02), NVS: 103.75 (-0.15)

Cellceutix Plans Clinical Trial in Patients With Ulcerative Proctitis
Marketwired - Mon Jan 26, 6:00AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, is pleased to announce that it is submitting a request early this week to the Food and Drug Administration (FDA) Division of Gastroenterology and Inborn Errors Products to conduct a pre-Investigational New Drug (IND) meeting to discuss development of a topical defensin-mimetic compound for the indication of induction of remission of ulcerative proctitis and ulcerative proctosigmoiditis.

Cellceutix: A December To Remember May Turn Into A 2015 To Forget For CTIX
Bleecker Street Research - at Seeking Alpha - Fri Jan 23, 9:30AM CST


Autism Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 6:36AM CST
The report "Autism - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Autism. Autism is known as a multifarious developmental disability. Autism disorder is characterized by social activities, non-verbal communication and repetitive behavior. Autism is highly transmissible but the cause includes both environmental factors and genetic susceptibility. It has long been assumed that there is a common cause at the genetic, cognitive and neural levels for autism's characteristic triad of symptoms. The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/autism-pipel...eport.html .
TEVA: 60.23 (-0.99), ITCI: 22.91 (-0.27), BCLI: 3.66 (-0.04), OMER: 20.88 (-0.01), NVS: 103.75 (-0.15)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BVM's Brookfield Headquarters Move Tests Growth Ambition

Updated Category News Views 13

A bigger office is rarely the exciting part of a growth story, yet it can reveal whether the machinery underneath is actually running hot. Best Version Media has moved its headquarters from Janacek Court to 15800 W. Bluemound Road, Suite 400, in Brookfield, Wisconsin, citing room for recent hires, future recruitment and closer collaboration across its print and digital...

Continue Reading
Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 145

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
Panama City Beach Rentals: Rules Before the Ocean View

Updated Category News Views 25

A postcard-perfect balcony can hide a remarkably expensive rulebook. That is the unglamorous message in Angie Outlaw’s discussion of vacation-property buying in Panama City Beach: the view may sell the unit, but zoning, association documents, insurance and lender terms determine whether the purchase behaves anything like the income-producing asset a buyer pictured. I...

Continue Reading
TRUSTA Targets AI Inference's GPU Memory Squeeze Hard

Updated Category News Views 103

GPU scarcity has turned ordinary server parts into strategic assets, and TRUSTA is leaning right into that uncomfortable fact at SuperComputing 2026. The enterprise-storage brand under ADATA is pitching an upgraded AI Scaler Toolkit built around a fairly sensible premise: companies running large-language-model inference should not have to buy another armful of expensive...

Continue Reading
Pacific Surfliner Faces Thanksgiving Capacity Test

Updated Category News Views 49

Thanksgiving traffic on Southern California freeways is its own yearly punishment, and the Pacific Surfliner is making a sensible pitch: leave the car parked and let the coast roll past the window. For travelers, that can be a real relief. For anyone watching public transportation, this is also a useful little stress test of whether a busy state-supported rail corridor...

Continue Reading
Rochester Truck Crashes Demand a Different Liability Map

Updated Category News Views 109

An 80,000-pound rig does not leave anybody the luxury of treating a wreck like a bent-fender dispute. That is the uncomfortable point behind Rochester attorney John Wright's discussion of truck crashes around I-390 and I-490. The physical damage may be obvious, but the legal story can be buried in dispatch systems, maintenance files, driver logs and corporate decisions...

Continue Reading
Snowrise Targets the Blind Spots in CPG Sales Data

Updated Category News Views 84

A sales total can look healthy while the floorboards are quietly rotting underneath it. That is the uncomfortable CPG problem Snowrise is aiming at: brands know what moved last quarter, but often cannot identify which stores, channels, communities, or promotions actually created the result. Plenty of management teams still steer by topline revenue, net distribution gains,...

Continue Reading
A €18 Million Mecca Chandelier Tests Austrian Craft

Updated Category News Views 171

Scale Is Easy to Boast About, Delivery Is Not A 34.1-metre chandelier hanging in Mecca is the sort of job that makes ordinary project talk sound downright silly. Lights of Vienna says it designed, built, tested, shipped and installed this monster for the Grand Mosque's Shamiya area, with a contract value of roughly €18 million. That is a serious piece of work for a...

Continue Reading
Kids First Data Sharing Raises Pediatric Research Bar

Updated Category News Views 73

Thirty-eight thousand children’s records are not a headline gimmick; they are a serious argument for treating research data as an asset that must keep working after the first study ends. The Gabriella Miller Kids First Data Resource Center’s ten-year review, published in the September 2026 issue of The American Journal of Human Genetics, makes that argument with...

Continue Reading
Markel's $2.5 Billion Buyback Adds Capital Flexibility

Updated Category News Views 37

A Large Checkbook, Not a Purchase Order Markel just handed management another $2.5 billion of repurchase firepower, and that deserves attention without the usual buyback cheerleading. The Board approved an increase to the existing authorization on November 18, 2026. That is a meaningful capital-allocation signal from a company built around specialty insurance,...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Heart Device Developments: Anteris Reports Growth

Updated Category News Views 316

Focus on Innovative Heart Valve Technology Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR), a pioneering force in cardiac care, has made significant strides in Q1, showcasing its commitment to innovation in heart valve technology. The company, based in both Australia and the United States, is devoted to revolutionizing cardiac treatment through advanced device...

Continue Reading
X-Bow and AEON Forge Alliance for Tactical Missile Systems

Updated Category News Views 321

X-Bow and AEON Forge Alliance for Tactical Missile Systems X-Bow Systems Inc (NASDAQ: X-Bow), a pioneer in advanced solid rocket motors and defense technologies, has embarked on an exciting new journey. The company recently announced a strategic partnership with AEON Industrial Inc., a firm dedicated to developing innovative defense solutions. Together, they are set to...

Continue Reading
Exciting Developments Ahead for Apollo's Stockholders Meeting

Updated Category News Views 280

Apollo's Upcoming Annual Meeting of Stockholders Apollo, a leading asset management firm, is gearing up for its 2025 Annual Meeting of Stockholders. This highly anticipated event will be conducted virtually on June 6, 2025, starting at 9:30 am ET. Stockholders are encouraged to participate, as the meeting will provide a platform for key updates and insights from the...

Continue Reading
Navigating Challenges: John B. Sanfilippo & Son, Inc. Insights

Updated Category News Views 353

JBSS Stock Experiences Recent Low Amid Economic Changes As the market presents ongoing challenges for investors, John B. Sanfilippo & Son, Inc. (JBSS) has hit a new 52-week low, now trading at $88.55. This established company, recognized for its diverse nut and snack offerings, has seen a turbulent year in trading with a slight 1.27% decrease in value over the past year....

Continue Reading
AnswerRocket Enhances Analytics Platform with New AI Models

Updated Category News Views 168

AnswerRocket adds Gemini and Claude language models to boost analytics AnswerRocket is expanding its analytics platform with advanced language models, integrating the Gemini LLMs and the Anthropic Claude family. The goal is simple: give businesses real choice in how they work with data. With these options, teams can pick the model that best fits a given problem, rather...

Continue Reading